| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2023 | 19.37% | Needham | → $35 | Initiates Coverage On | → Buy |
| 11/13/2023 | 9.14% | Stifel | $35 → $32 | Maintains | Hold |
| 11/10/2023 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 11/07/2023 | 22.78% | Goldman Sachs | $42 → $36 | Maintains | Neutral |
| 11/03/2023 | 39.84% | Barrington Research | $51 → $41 | Maintains | Outperform |
| 11/03/2023 | 33.02% | Morgan Stanley | $43 → $39 | Maintains | Overweight |
| 11/01/2023 | 19.37% | Stifel | $41 → $35 | Maintains | Hold |
| 10/20/2023 | 46.66% | Morgan Stanley | $47 → $43 | Maintains | Overweight |
| 09/22/2023 | 33.02% | Piper Sandler | $42 → $39 | Maintains | Neutral |
| 08/04/2023 | 73.94% | Barrington Research | → $51 | Reiterates | → Outperform |
| 05/04/2023 | 73.94% | Barrington Research | $43 → $51 | Reiterates | → Outperform |
| 05/04/2023 | 39.84% | Stifel | $37 → $41 | Maintains | Hold |
| 05/04/2023 | 60.3% | Morgan Stanley | $45 → $47 | Maintains | Overweight |
| 05/04/2023 | 56.89% | Baird | $36 → $46 | Maintains | Neutral |
| 04/19/2023 | 53.48% | Morgan Stanley | $39 → $45 | Maintains | Overweight |
| 03/02/2023 | 33.02% | Goldman Sachs | $34 → $39 | Maintains | Neutral |
| 03/01/2023 | 33.02% | Goldman Sachs | $34 → $39 | Maintains | Neutral |
| 02/06/2023 | 19.37% | Piper Sandler | $29 → $35 | Maintains | Neutral |
| 01/12/2023 | — | William Blair | Upgrades | Underperform → Market Perform | |
| 11/16/2022 | 15.96% | Goldman Sachs | $41 → $34 | Maintains | Neutral |
| 11/15/2022 | 33.02% | Morgan Stanley | $42 → $39 | Maintains | Overweight |
| 10/13/2022 | 43.25% | Morgan Stanley | $44 → $42 | Maintains | Overweight |
| 08/05/2022 | — | William Blair | Downgrades | Market Perform → Underperform | |
| 07/21/2022 | 39.84% | Goldman Sachs | $42 → $41 | Maintains | Neutral |
| 07/20/2022 | 50.07% | Morgan Stanley | $48 → $44 | Maintains | Overweight |
| 06/02/2022 | 60.3% | UBS | $58 → $47 | Upgrades | Neutral → Buy |
| 05/11/2022 | 63.71% | Morgan Stanley | $52 → $48 | Maintains | Overweight |
| 04/22/2022 | 63.71% | HC Wainwright & Co. | $58 → $48 | Maintains | Neutral |
| 04/21/2022 | 60.3% | Goldman Sachs | $59 → $47 | Maintains | Neutral |
| 04/20/2022 | 77.35% | Morgan Stanley | $62 → $52 | Maintains | Overweight |
| 04/20/2022 | 67.12% | B of A Securities | $66 → $49 | Downgrades | Buy → Neutral |
| 04/20/2022 | 56.89% | Piper Sandler | $71 → $46 | Downgrades | Overweight → Neutral |
| 04/19/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 04/19/2022 | 63.71% | Baird | → $48 | Downgrades | Outperform → Neutral |
| 04/19/2022 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 03/01/2022 | 101.23% | Goldman Sachs | $66 → $59 | Maintains | Neutral |
| 03/01/2022 | 128.51% | Credit Suisse | $68 → $67 | Maintains | Outperform |
| 02/18/2022 | 128.51% | Baird | $78 → $67 | Maintains | Outperform |
| 01/31/2022 | 111.46% | Morgan Stanley | → $62 | Initiates Coverage On | → Overweight |
| 08/09/2021 | 125.1% | HC Wainwright & Co. | $72 → $66 | Maintains | Neutral |
| 05/07/2021 | 145.57% | HC Wainwright & Co. | $60 → $72 | Maintains | Neutral |
| 03/02/2021 | 142.16% | Barrington Research | → $71 | Upgrades | Market Perform → Outperform |
| 01/05/2021 | 87.59% | HC Wainwright & Co. | $49 → $55 | Maintains | Neutral |
| 12/18/2020 | 77.35% | Stifel | → $52 | Downgrades | Buy → Hold |
| 11/17/2020 | 36.43% | Barclays | → $40 | Downgrades | Equal-Weight → Underweight |
| 11/09/2020 | 67.12% | HC Wainwright & Co. | $45 → $49 | Maintains | Neutral |
| 10/22/2020 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 07/20/2020 | 91% | B of A Securities | $54 → $56 | Maintains | Buy |
| 06/16/2020 | 73.94% | Piper Sandler | → $51 | Initiates Coverage On | → Overweight |
| 06/15/2020 | 70.53% | HC Wainwright & Co. | $38 → $50 | Maintains | Neutral |
| 05/27/2020 | 70.53% | Evercore ISI Group | → $50 | Upgrades | In-Line → Outperform |
| 05/14/2020 | 29.6% | CFRA | $53 → $38 | Maintains | Hold |
| 05/11/2020 | 36.43% | Barclays | $42 → $40 | Maintains | Equal-Weight |
| 05/11/2020 | 50.07% | UBS | $59 → $44 | Maintains | Neutral |
| 04/24/2020 | 29.6% | HC Wainwright & Co. | $51 → $38 | Reiterates | → Neutral |
| 04/08/2020 | 67.12% | Baird | $57 → $49 | Upgrades | Neutral → Outperform |
| 04/02/2020 | 125.1% | Wolfe Research | → $66 | Upgrades | Peer Perform → Outperform |
| 03/17/2020 | 53.48% | JP Morgan | $65 → $45 | Maintains | Neutral |
| 03/13/2020 | 91% | Stifel | $66 → $56 | Maintains | Buy |
| 03/03/2020 | 94.41% | Baird | $61 → $57 | Maintains | Neutral |
| 03/03/2020 | 73.94% | HC Wainwright & Co. | $60 → $51 | Reiterates | → Neutral |
| 12/16/2019 | 125.1% | Goldman Sachs | → $66 | Maintains | Buy |
| 12/11/2019 | 121.69% | JP Morgan | → $65 | Downgrades | Overweight → Neutral |
| 11/08/2019 | 97.82% | Barclays | $55 → $58 | Maintains | Equal-Weight |
| 11/08/2019 | 114.87% | Stifel | $61 → $63 | Maintains | Buy |
| 07/26/2019 | — | Evercore ISI Group | Initiates Coverage On | → In-Line | |
| 04/18/2019 | 84.17% | Guggenheim | → $54 | Initiates Coverage On | → Neutral |
| 03/18/2019 | 94.41% | B of A Securities | → $57 | Reinstates | → Buy |
| 03/18/2019 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 03/12/2019 | 80.76% | UBS | $42 → $53 | Maintains | Neutral |
| 03/04/2019 | 70.53% | Baird | $42 → $50 | Maintains | Neutral |
| 01/17/2019 | 43.25% | UBS | → $42 | Initiates Coverage On | → Neutral |
What is the target price for Dentsply Sirona (XRAY)?
The latest price target for Dentsply Sirona (NASDAQ: XRAY) was reported by Needham on November 16, 2023. The analyst firm set a price target for $35.00 expecting XRAY to rise to within 12 months (a possible 19.37% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dentsply Sirona (XRAY)?
The latest analyst rating for Dentsply Sirona (NASDAQ: XRAY) was provided by Needham, and Dentsply Sirona initiated their buy rating.
When is the next analyst rating going to be posted or updated for Dentsply Sirona (XRAY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dentsply Sirona, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dentsply Sirona was filed on November 16, 2023 so you should expect the next rating to be made available sometime around November 16, 2024.
Is the Analyst Rating Dentsply Sirona (XRAY) correct?
While ratings are subjective and will change, the latest Dentsply Sirona (XRAY) rating was a initiated with a price target of $0.00 to $35.00. The current price Dentsply Sirona (XRAY) is trading at is $29.32, which is within the analyst's predicted range.